Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine composition of trifusal and clopidogrel

A technology of clopidogrel and composition, which is applied in the field of pharmaceutical composition containing these two active ingredients, and can solve problems such as allergies and increased risks

Inactive Publication Date: 2007-01-03
陈文展
View PDF0 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] However, the use of aspirin is also limited clinically. For example, many patients are allergic to aspirin; the risk of upper gastrointestinal bleeding is doubled when aspirin is used in the antithrombotic dose range of 75-100mg / d. Other means such as enteric coating and taking with food cannot solve the problem

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Example 1: Preparation of Triflusal and Clopidogrel Compound Soft Capsules

[0025] Take 150g of triflusalox and 50g of clopidogrel, mix them evenly, add 300g of soybean oil, 6g of beeswax, mix them evenly, and make 1000 soft capsules.

Embodiment 2

[0026] Example 2: Preparation of Triflusal and Clopidogrel Compound Soft Capsules

[0027] The same prescription ratio as in Example 1 is: 350 g of triflusal and 50 g of clopidogrel are made into 1000 capsules.

Embodiment 3

[0028] Example 3: Preparation of Triflusal and Clopidogrel Compound Soft Capsules

[0029] The same prescription ratio as in Example 1 is: 100 g of triflusal and 300 g of clopidogrel are made into 1000 capsules.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The medicine composition has synergistic active components trifusal and clopidogrel, and its clopidogrel exists in free state or pharmaceutically acceptable salt. The medicine composition is used in treating stable or unstable angina pectoris and other cardiac and cerebral vascular diseases. Pharmaceutical experiments prove the synergistic effect of trifusal and clopidogrel in the medicine composition and the medicine composition has blood platelet inhibiting rate superior to that of aspirin-clopidogrel composition and high safety suitable for long -term taking.

Description

Technical field: [0001] The present invention relates to a novel combination with anti-platelet aggregation activity consisting of triflusalox and clopidogrel, and a pharmaceutical composition containing the two active ingredients. Background technique: [0002] Vascular disease is a systemic disease. The clinical manifestations are different due to the different sites of thrombosis. A vascular event occurs in one vessel, which means that the risk of vascular events in other vessels increases. According to statistics, the death caused by atherosclerotic thrombosis accounts for 28.7% of the total death of the population, mainly due to coronary artery events and cerebral artery events, followed by other peripheral arterial diseases, and two or even three vascular lesions may coexist . The pathological basis of vascular events is atherosclerosis, and the first step in pathophysiology is platelet activation. Therefore, antiplatelet therapy is crucial for the prevention of vascu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4365A61K31/216A61K9/20A61K9/48A61K9/16A61P7/02A61P9/10
Inventor 陈文展
Owner 陈文展
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com